Phase I/II trial of Alpha-galactosidase (MOSS-AGAL) in patients with Fabry Disease

Trial Profile

Phase I/II trial of Alpha-galactosidase (MOSS-AGAL) in patients with Fabry Disease

Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 Sep 2016

At a glance

  • Drugs Alpha galactosidase (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Sep 2016 New trial record
    • 09 Mar 2015 According to a Greenovation Biotech media release, company is working on our regulatory package for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top